Trials of New Pneumococcal Vaccines in Gambian Children and Infants

PI: Aderonke Odutola (MRC Unit, The Gambia)
Funders
: PATH

This study is investigating whether addition of two proteins found in all pneumococci (pneumolysin and histidine triad protein)  to the 10-valent pneumococcal conjugate vaccine produced by GlaxoSmithKline (PCV10) can increase the ability of this vaccine to provide protection against pneumococci of serotypes not represented in the vaccine. The trial is being conducted in Fajikunda on the Gambian coast and involves 1200 infants randomly allocated to five groups to investigate different immunisation schedules and antigen doses. The primary end-point of the trial is nasopharyngeal carriage of pneumococci. All clinical work has been completed and the vaccine has been shown to be immunogenic and safe. Laboratory work, including measurement of the impact of the vaccine on carriage density, measured by qPCR , will be completed in the middle of 2014.

Back